'''Capeserod''' ([[International nonproprietary name|INN]],<ref>{{cite web|title=WHO Drug Information. Vol. 20, No. 3, 2006. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 56|url=http://apps.who.int/medicinedocs/documents/s14181e/s14181e.pdf|publisher=World Health Organization|accessdate=25 April 2016|page=208}}</ref> previously known as '''SL65.0155''') is a [[binding selectivity|selective]] [[5-HT4 receptor|5-HT<sub>4</sub> receptor]] [[partial agonist]] with [[Dissociation constant|K<sub>i</sub>]] = 0.6 nM and [[Intrinsic activity|IA]] = 40–50% (relative to serotonin).<ref name="pmid12130738">{{cite journal  |vauthors=Moser PC, Bergis OE, Jegham S, etal | title = SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 302 | issue = 2 | pages = 731–41 |date=August 2002 | pmid = 12130738 | doi = 10.1124/jpet.102.034249 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=12130738}}</ref> It potently enhances [[cognition]], [[learning]], and [[memory]],<ref name="pmid12130738"/><ref name="pmid15489027">{{cite journal  |vauthors=Spencer JP, Brown JT, Richardson JC, etal | title = Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease | journal = Neuroscience | volume = 129 | issue = 1 | pages = 49–54 | year = 2004 | pmid = 15489027 | doi = 10.1016/j.neuroscience.2004.06.070 | url = http://linkinghub.elsevier.com/retrieve/pii/S0306-4522(04)00623-2}}</ref><ref name="pmid17011531">{{cite journal | vauthors = Micale V, Leggio GM, Mazzola C, Drago F | title = Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia | journal = Brain Research | volume = 1121 | issue = 1 | pages = 207–15 |date=November 2006 | pmid = 17011531 | doi = 10.1016/j.brainres.2006.08.108 | url = http://linkinghub.elsevier.com/retrieve/pii/S0006-8993(06)02658-8}}</ref><ref name="pmid18075492">{{cite journal | vauthors = Restivo L, Roman F, Dumuis A, Bockaert J, Marchetti E, Ammassari-Teule M | title = The promnesic effect of G-protein-coupled 5-HT4 receptors activation is mediated by a potentiation of learning-induced spine growth in the mouse hippocampus | journal = Neuropsychopharmacology | volume = 33 | issue = 10 | pages = 2427–34 |date=September 2008 | pmid = 18075492 | doi = 10.1038/sj.npp.1301644 }}</ref><ref name="pmid18485752">{{cite journal  |vauthors=Marchetti E, Jacquet M, Jeltsch H, etal | title = Complete recovery of olfactory associative learning by activation of 5-HT4 receptors after dentate granule cell damage in rats | journal = Neurobiology of Learning and Memory | volume = 90 | issue = 1 | pages = 185–91 |date=July 2008 | pmid = 18485752 | doi = 10.1016/j.nlm.2008.03.010 | url = http://linkinghub.elsevier.com/retrieve/pii/S1074-7427(08)00059-2}}</ref><ref name="pmid18765258">{{cite journal | vauthors = Hille C, Bate S, Davis J, Gonzalez MI | title = 5-HT4 receptor agonism in the five-choice serial reaction time task | journal = Behavioural Brain Research | volume = 195 | issue = 1 | pages = 180–6 |date=December 2008 | pmid = 18765258 | doi = 10.1016/j.bbr.2008.08.007 | url = http://linkinghub.elsevier.com/retrieve/pii/S0166-4328(08)00436-1}}</ref> and also possesses [[antidepressant]] effects.<ref name="pmid19596038">{{cite journal | vauthors = Tamburella A, Micale V, Navarria A, Drago F | title = Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats | journal = Progress in Neuro-psychopharmacology & Biological Psychiatry | volume = 33 | issue = 7 | pages = 1205–10 |date=October 2009 | pmid = 19596038 | doi = 10.1016/j.pnpbp.2009.07.001 | url = http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(09)00215-2}}</ref> Capeserod was in [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s around 2004–2006 for the treatment of [[Amnesia|memory deficit]]s and [[dementia]] but no new information has surfaced since and it appears to have been abandoned.<ref name="pmid14965243">{{cite journal | vauthors = Bockaert J, Claeysen S, Compan V, Dumuis A | title = 5-HT4 receptors | journal = Current Drug Targets. CNS and Neurological Disorders | volume = 3 | issue = 1 | pages = 39–51 |date=February 2004 | pmid = 14965243 | doi = 10.2174/1568007043482615| url = }}</ref><ref name="isbn1-58829-568-0">{{cite book | author = Roth, Bryan L. | title = The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics (The Receptors) | publisher = Humana Press | location = Totowa, NJ | year = 2006 | pages = | isbn = 1-58829-568-0 | oclc = | doi = | url = https://books.google.com/books?id=J6i6YpvCQfIC&lpg=PA472&ots=83um0yH2Yr&dq=SL65.0155%20phase%20II&pg=PA472#v=onepage&q=&f=false}}</ref>
